11/10/2022
XTX202 Poster Presentation at the 2022 Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting
XTX202, a tumor-selective protein-engineered IL-2, exhibited enhanced anti-tumor activity in combination with checkpoint inhibition in mice

Read more >

06/05/2022
XTX202 Poster Presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
A First-in-Human, Multicenter, Phase 1/2, Open-Label Study of XTX202, a Tumor-Selective Interleukin-2 (IL-2), in Patients with Advanced Solid Tumors

Read more >

05/10/2022
XTX301 Poster Presentation at the New York Academy of Sciences’ Frontiers in Cancer Immunotherapy 2022 Conference
A half-life extended, tumor selective IL-12 activated tumor infiltrating immune cells and demonstrated anti-tumor activity in the MC38 syngeneic mouse model

Read more >

11/12/2021
XTX301 Poster Presentation at the Society for Immunotherapy in Cancer’s 36th Annual Meeting (SITC)
XTX301, A Protein-engineered IL-12, Exhibits Tumor-selective Activity In Mice Without Peripheral Toxicities And Is Well Tolerated In Non-Human Primates

Read more >

11/12/2021
XTX101 (CTLA-4) Poster Presentation at the Society for Immunotherapy in Cancer’s 36th Annual Meeting (SITC)
A First-in-Human, Multicenter, Phase 1/2, Open-Label Study of XTX101 in Patients with Advanced Solid Tumors

Read more >

09/22/2021
Presentation at the Next-Gen Cytokine Therapeutics Summit
Tumor selective cytokines for cancer therapy

Read more >

06/08/2021
XTX202 (IL-2) Poster Presentation at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting
XTX202, a protein-engineered IL-2, exhibits tumor-selective activity in mice without peripheral toxicities in non-human primates

Read more >

05/12/2021
XTX101 (CTLA-4) Poster Presentation at The New York Academy of Sciences’ Frontiers in Cancer Immunotherapy 2021 Virtual Symposium
Tumor-Activated Anti-CTLA-4 Monoclonal Antibody, XTX101, Demonstrates Monotherapy and Anti-PD-1 Combination Benefit in Preclinical Models

Read more >

11/13/2020
XTX101 (CTLA-4) Poster Presentation at 35th Annual Meeting of The Society for Immunotherapy of Cancer
Tumor-activated Fc-engineered Anti-CTLA-4 Monoclonal Antibody, XTX101, Demonstrates Tumor-selective PD and Efficacy in Preclinical Models

Read more >

11/12/2020
XTX201 (IL-2) Poster Presentation at 35th Annual Meeting of The Society for Immunotherapy of Cancer
XTX201, a protein-engineered IL-2, exhibits tumor-selective activity in mice without peripheral toxicities in non-human primates

Read more >